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Original Article

Saccharomyces boulardii and bismuth
subsalicylate as low-cost interventions to
reduce the duration and severity of cholera
Johnathan Sheele1, Jessica Cartowski2, Angela Dart3, Arjun Poddar4,
Shikha Gupta5, Eric Stashko6, Bhaskara S. Ravi4, Crawford Nelson7,
Ajay Gupta8
1

Department of Emergency Medicine, University Hospitals Case Medical Center & Case Western Reserve
University, Cleveland, OH, USA, 2Eastern Virginia Medical School and Emergency Physicians of Tidewater, VA,
USA, 3International Health Programs Operation Blessing International, Virginia Beach, VA, USA, 4Eastern
Virginia Medical School Epidemiology-Biostatistics Research Support Core, VA, USA, 5University of Virginia
School of Medicine, VA, USA, 6Department of Emergency Medicine, Beth Israel Deaconess Medical Center,
Boston, MA, USA, 7Operation Blessing International, Virginia Beach, VA, USA, 8Department of Computer
Science, Old Dominion University, Norfolk, VA, USA
We conducted a randomised single-blinded clinical trial of 100 cholera patients in Port-au-Prince, Haiti to
determine if the probiotic Saccharomyces cerevisiae var. boulardii and the anti-diarrhoeal drug bismuth
subsalicylate (BS) were able to reduce the duration and severity of cholera. Subjects received either:
S. boulardii 250 mg, S. boulardii 250 mg capsule plus BS 524 mg tablet, BS 524 mg, or two placebo
capsules every 6 hours alongside standard treatment for cholera. The length of hospitalisation plus the
number and volume of emesis, stool and urine were recorded every 6 hours until the study subject was
discharged (n583), left against medical advice (n511), or requested removal from the study (n56).
There were no reported deaths or adverse study-related events. There were no statistically significant
differences between the study arms and the outcomes of interest.
Keywords: Cholera, Bismuth subsalicylate, Saccharomyces boulardii, Diarrhoea, Cholera toxin, Treatment, Probiotic

Introduction
Vibrio cholerae is a gram-negative bacterium that
causes clinical cholera by a producing cholera toxin
(CT). Cholera toxin increases adenylate cyclase
activity resulting in increased intracellular cyclic adenosine monophosphate (cAMP) leading to an efflux
of chloride ions and secretion of water, sodium, potassium and bicarbonate into the intestinal lumen.
Cholera is characterised by a sudden onset of
watery diarrhoea that may be accompanied by
vomiting.1 Cholera is highly contagious, and in
severe disease stool volumes of 500–1000 ml/hour
can result in dehydration.1
In January 2010, Haiti suffered a 7.0 magnitude
earthquake. In October 2010, an outbreak of cholera
ensued infecting about 700 000 Haitians and killing
8500.2 Early in the cholera outbreak Operation

Correspondence to: Johnathan Sheele, Department of Emergency
Medicine, Global Emergency Medicine, University Hospitals Case
Medical Center, Case Western Reserve University, 11100 Euclid Ave.,
B-517K, Cleveland, OH 44106, USA. Email: jsheele@gmail.com

ß W. S. Maney & Son Ltd 2015
DOI 10.1179/2047773215Y.0000000028

Blessing International, a non-governmental organisation working with St. Luc hospital outside Portau-Prince Haiti, established a cholera rehydration
centre.
Cholera affects several million people each year in
developing countries without access to clean water or
sanitation.3 Untreated cholera mortality can
approach 50%, but treatment with oral rehydration
solution (ORS) to prevent dehydration drops the
mortality rate to below 4%.3 Oral rehydration solution contains salts and glucose to augment fluid
absorption from the intestine by the sodium glucose
cotransporter-1. The addition of zinc supplements
and antibiotics also have been shown to be beneficial
in the treatment of cholera.4,5
For decades, probiotics – defined as a live microorganism that confers benefit to the host – have been
utilised in humans to treat and prevent gastrointestinal diseases. Saccharomyces cerevisiae var. boulardii
hence referred to as S. boulardii is one of the best-studied probiotics that has been used to treat diarrhoea
by many millions of people worldwide as an over-
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the-counter supplement. Lyophilised S. boulardii is
resistant to antibiotics, survives optimally at 37uuC,
is resistant to gastric acidity and proteolysis, reaches
steady state concentrations within the stool in 3 days,
and is cleared from the stools within 2–5 days.6 While
S. boulardii has never been evaluated clinically to
determine efficacy for treatment against cholera in
humans, it has been the subject of multiple clinical
trials, meta-analysis, and expert consensus guidelines
for managing gastrointestinal illnesses in children
and adults.7–13
S. boulardii augments gastrointestinal immunity by
reducing inflammation and improving humoural
immunity, inhibits some bacterial toxins, and
enhances the activity of the sodium glucose cotransporter-1.14 When pretreated with S. boulardii,
Fischer rats are largely protected from the clinical
effects of CT.15,16 The effects of CT on isolated
loop jejunum secretion was reduced by the addition
of S. boulardii.17,18 S. boulardii also protects cultured
intestinal
cells
against
CT-induced
cAMP
elevation.17,19,20
Bismuth subsalicylate (BS) is sold over the counter
in the United States under several brand names
including Pepto-BismolH. Bismuth subsalicylate is
used to treat diarrhoea, acid reflux, gastritis and
Helicobacter pylori infection in individuals over the
age of 12 years. Bismuth subsalicylate is postulated
to provide benefit by a number of mechanisms
including coating the intestines to prevent intestinal
secretion and promote fluid absorption, reducing
inflammation, binding toxins and killing some bacteria. Fluid accumulation in ligated and unligated
rabbit and pig intestinal segments was substantially
reduced when BS was added before, but not after,
the addition of CT.21 Similarly, BS significantly
reduces the effects of CT when BS administered
before CT receptor binding in Y-1 adrenal cell
tissue and rabbit ligated intestinal loops.22
Since cholera affects individuals living in economically disadvantaged areas of the world, interventions
to reduce the duration and severity of disease must be
inexpensive, safe, non-technical and readily available.
Two medications that fit these requirements are BS
and S. boulardii, both of which already have been
shown to be safe and efficacious in treating other
diarrhoeal diseases. The purpose of our study was
to evaluate BS and S. boulardii to determine if they
would be efficacious against cholera.

Methods
Ethical considerations
We received institutional review board (IRB)
approval from Eastern Virginia Medical School
(11-04-FB-0097). We were unable to identify a local
ethical review board affiliated with St. Luc hospital
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in Port-au-Prince, Haiti, so administrators at both
St. Luc and Operation Blessing International
reviewed and approved the study. The study took
place from September to October 2011 at St. Luc
hospitals.

Experimental
The primary objectives of this study were to determine if the study interventions were able to reduce
the duration of cholera-symptoms as defined by the
total number of hours in the cholera rehydration
centre, reduce the mean number of stools, and
reduce the volume of stools when compared to placebos. The study inclusion criteria were: (1) nonpregnant and non-breastfeeding persons aged 12–
89 years old; (2) onset of cholera symptoms for
v3 days; and (3) subjects had not taken any medications to treat cholera. Study exclusion criteria
included: (1) clinical diagnostic uncertainty about
having cholera; (2) unable to obtain informed consent from study subject (including the subject’s guardian if under age 18 years old); (3) allergy to BS,
aspirin, doxycycline, promethazine, non-steroidal
anti-inflammatory drugs or yeast; or (4) currently
taking methotrexate due to a potential drug interaction with BS.
A Haitian research assistant fluent in Creole, English, and French approached potential study subjects
within 4 hours of arrival to the rehydration centre.
Study participation did not interfere with clinical
management and subjects too ill to consent were
excluded. Subjects were consented using otherwise
identical consent forms in Creole, English and
French. All study subjects had a positive stoolbased rapid enzyme-linked immunoassay (ELISA)
test for V. cholerae (Crystal VC, Span Diagnostics,
Ltd., Surat, Gujarat, India) before study enrolment.
All patients screened for study enrolment with a
diagnosis of clinical cholera tested positive by the
cholera ELISA test. In addition, all female study subjects of reproductive age had a negative urine pregnancy test. Routine laboratory tests are not
performed as part of the standard management for
cholera patients at St. Luc hospital, and aside from
urine pregnancy tests and stool ELISA tests for cholera, we did not perform additional laboratory investigations on our subjects.
Study subjects were randomised to one of four
treatment arms using a random number generator.
Study drugs were given by mouth every 6 hours by
a nurse from an envelope labelled with a number corresponding to the treatment arm that the subject was
randomised. The study subject, nurse and physician,
but not the research assistant recording the data,
were blinded to the treatment arm of the study subject. The treatment arms were: (1) S. boulardii

3
4
3

1

2
3
0

1

19
23
19
22

84 (SD ¼ 18)
32 (SD ¼ 18)
83 (SD ¼ 13)
42 (SD ¼ 28)
80 (SD ¼ 12)
41 (SD ¼ 22)

84 (SD ¼ 13)
42 (SD ¼ 31)

29 (SD ¼ 17)
33 (SD ¼ 18)
23 (SD ¼ 18)

26 (SD ¼ 17)

58%
58%
48%

44%

32 (SD ¼ 16)
54%
28 (SD ¼ 10)
68%
35 (SD ¼ 15)
62%
39 (SD ¼ 15)
48%

BS (n ¼ 25)
SB (n ¼ 26)
SB and BS (n ¼ 25)
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One hundred fifteen persons were approached for
study participation, of which 100 study subjects
were enrolled for greater than 6 hours. The baseline
characteristics for our study subjects were similar
(Table 1). Based on the average heart rates, initial
reported urine frequency and urine volumes suggest
that our study subjects were not severely dehydrated.
The mean outcome measurements for each treatment
arm, recorded every 6 hours, is displayed in Table 2.
Study subjects left the study for one of the following reasons: death (n50); discharge from the hospital

Duration and severity of cholera

Age
Percentage of study subjects that were
male
Percentage of study subjects receiving promethazine
at enrolment
Number of hours of diarrhoea prior
to study enrolment
Heart rate at time of enrolment
Number of hours study subject participated
in the study
Number of study subjects ultimately discharged
from study
Number of study subjects asking to
be taken out of the study
Number of study subjects leaving the
before hospital discharge (i.e. left against medical advice or
eloped)

Results

Table 1 Characteristics of the study subjects

250 mg
capsule
(Advanced
Orthomolecular
Research, Calgary, AB, Canada) plus a placebo capsule (empty gel capsule); (2) S. boulardii 250 mg capsule plus two BS (Pepto-BismolH, Proctor and
Gamble, Cincinnati, OH, USA chewable 262 mg
tablets); (3) two BS 262 mg tablets plus a placebo
capsule; or (4) two placebo capsules. All study subjects received zinc 5 mg by mouth every 6 hours
along with the study drugs.
A cholera treatment protocol developed and
approved by St. Luc hospital prior to initiation of
this research study was followed for the management
of all patients with cholera, including our study subjects. All study interventions were provided in
additional to the standard of care treatment provided
at the hospital. The cholera treatment protocol consisted of the administration of ORS ad lib to all
patients. If the treating physician determines that
the person is not severely dehydrated based on clinical criteria, but the patient vomits, then that patient
will receive 2 L of intravenous ringer’s lactate over
60 minutes with additional intravenous fluids given
at the discretion of the treating physician. Patients
with severe dehydration receive 4 L of intravenous
ringer’s lactate over 2 hours and then 4 L over
4 hours with additional intravenous fluids administered as clinically indicated by the treating physician.
All patients, including our study subjects, received a
single 300 mg dose of oral doxycycline when
admitted to the rehydration centre.
In summary, study subjects received the same
resuscitation and medical treatment for cholera as
non-study subjects with cholera with the exception
that study subjects received: (1) possible urine pregnancy test; (2) stool ELISA to confirm cholera; (3)
optional single-dose oral promethazine 6.25 mg at
the time of study enrolment; (4) study drugs every
6 hours; (5) zinc 5 mg orally every 6 hours; (6)
measurement of the number and volume of stool,
urine and emesis every 6 hours; (7) record of selfreported duration of cholera-symptoms prior to arrival at the cholera rehydration centre and (8) the time
and reason for leaving the study.

Placebo (n ¼ 24)
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BS
P
SB

SB þ BS

SB

P

BS
P
SB
SB þ BS
BS

SB þ BS

SB

P

BS
P
SB
SB þ BS
BS

3.2 (2.6), n ¼ 10
3.2 (1.3), n ¼ 13
4.1 (3.4), n ¼ 17
3.2 (2.8), n ¼ 19
1758 (2665),
n ¼ 10
1455 (1270),
n ¼ 13
1363 (1070),
n ¼ 15
1502 (1245),
n ¼ 18
0 (0), n ¼ 10
0 (0), n ¼ 10
0.4 (1.2), n ¼ 17

24 Hours

53 (182), n ¼ 20 23 (90), n ¼ 15

88 (223), n ¼ 17 15 (55), n ¼ 13

0.1 (0.3), n ¼ 20 0 (0), n ¼ 19
0 (0), n ¼ 17
0 (0), n ¼ 10

2.6 (1.8), n ¼ 17
3.7 (2.8), n ¼ 19
4.8 (3.1), n ¼ 21
3.8 (2.5), n ¼ 20
1600 (2537),
n ¼ 16
1534 (1052),
n ¼ 14
1587 (1235),
n ¼ 18
1685 (1254),
n ¼ 20
0 (0), n ¼ 17
0 (0), n ¼ 7
0.4 (1.7), n ¼ 21

18 Hours

3.1 (1.9), n ¼ 25
3.3 (2.1), n ¼ 25
3.3 (2.9), n ¼ 26
2.4 (1.3), n ¼ 25
389 (276),
n ¼ 24
338 (203),
n ¼ 23
452 (466),
n ¼ 24
337 (236),
n ¼ 25

2.6 (2.1), n ¼ 20
2.9 (1.8), n ¼ 23
2.9 (2.5), n ¼ 25
3 (2.5), n ¼ 24
496 (625),
n ¼ 20
410 (255),
n ¼ 20
360 (356),
n ¼ 22
456 (489),
n ¼ 24

3.4 (2.2), n ¼ 17
2.8 (2.1), n ¼ 19
3.8 (2.2), n ¼ 21
3.3 (2.5), n ¼ 20
1884 (5713),
n ¼ 17
340 (256),
n ¼ 13
496 (355),
n ¼ 19
552 (703),
n ¼ 20

2.5 (1.4), n ¼ 10
2.9 (1.4), n ¼ 13
2.8 (2.2), n ¼ 14
2.8 (2.3), n ¼ 19
444 (379),
n ¼ 10
458 (480),
n ¼ 13
352 (201),
n ¼ 15
560 (579),
n ¼ 18

58 (182), n ¼ 25 29 (143), n ¼ 24 0.1 (0.3), n ¼ 19 0 (0), n ¼ 19

BS ¼ bismuth subsalicylate, P ¼ placebo, SB ¼ S. boulardii

Mean urine volume
(ml)

Mean number of
urine

SB þ BS

SB

3.3 (2.2), n ¼ 20
5.6 (8.4), n ¼ 23
4.0 (2.4), n ¼ 25
3.7 (2.5), n ¼ 24
1485 (1439),
n ¼ 20
1758 (1384),
n ¼ 20
2892 (3379),
n ¼ 25
1550 (1056),
n ¼ 25
0.2 (0.7), n ¼ 20
0.2 (0.7), n ¼ 20
0.4 (1.0), n ¼ 25

12 Hours

0.3 (1), n ¼ 25
0.1 (0.4), n ¼ 24
138 (512),
71 (296), n ¼ 20
n ¼ 24
65 (184), n ¼ 23 241 (803),
n ¼ 22
72 (192), n ¼ 25 76 (176), n ¼ 22

4 (2.8), n ¼ 25
4.5 (1.8), n ¼ 23
4.3 (2.4), n ¼ 26
3.8 (2.2), n ¼ 25
1646 (1147),
n ¼ 24
1907 (1199),
n ¼ 23
2132 (1769),
n ¼ 25
1384 (1080),
n ¼ 25
0.6 (1.6), n ¼ 25
0.6 (1.3), n ¼ 25
0.5 (1.3), n ¼ 26

Treatment 6 Hours

SB þ BS
Mean emesis volume BS
(ml)
P

Mean number of
emesis

Mean stool volume
(ml)

Mean number of
stools

Outcome
3.3 (2.3), n ¼ 2
3.5 (2.4), n ¼ 6
2.7 (2.8), n ¼ 9
2.9 (2.5), n ¼ 8
3667 (2566),
n¼2
1447 (1171),
n¼6
718 (768),
n¼9
903 (822),
n¼7
1.5 (1.7), n ¼ 2
1.5 (1.7), n ¼ 2
0.7 (1.0), n ¼ 9

42-48 Hours

2.2 (0.6), n ¼ 2
3.7 (2.2), n ¼ 6
1.6 (1.9), n ¼ 9
4.4 (3.3), n ¼ 8
933 (839),
n¼2
309 (228), n ¼ 5 966 (672),
n¼3
1109 (1512),
187 (225),
n ¼ 14
n¼9
758 (1088),
402 (367),
n¼7
n ¼ 13

2.9 (1.6), n ¼ 8
2.3 (1.7), n ¼ 10
3.3 (2.7), n ¼ 15
2.2 (2.2), n ¼ 14
605 (608), n ¼ 8

93 (168), n ¼ 13 357 (541),
n¼9
0 (0), n ¼ 12
0 (0), n ¼ 8

0.1 (0.3), n ¼ 14 0 (0), n ¼ 8
100 (200), n ¼ 8 750 (866),
n¼2
0 (288), n ¼ 6
0 (46), n ¼ 10

3.1 (1.7), n ¼ 8
2.7 (2.4), n ¼ 10
4.2 (3.5), n ¼ 15
3.2 (2.3), n ¼ 14
1790 (1632),
n¼8
1081 (891),
n ¼ 10
2748 (2158),
n ¼ 14
1644 (1263),
n ¼ 14
0.1 (0.3), n ¼ 8
0.1 (0.3), n ¼ 8
0.5 (1.2), n ¼ 15

30–36 Hours

Table 2 Mean value for each treatment arm, (standard deviation), and n 5 number of study subjects with available data

1097 (1110),
n¼3

150 (100),
n¼2

125 (144),
n¼2
4.5 (0), n ¼ 1
11 (3.5), n ¼ 1
4.5 (2.4), n ¼ 5
4.5 (1.8), n ¼ 3
2.8 (1.6), n ¼ 5
4.4 (1.2), n ¼ 3
2.8 (1.4), n ¼ 3
2.5 (2.1), n ¼ 2
1400 (283), n ¼ 1 2210 (1117),
n¼1
533 (366), n ¼ 3 1035 (541),
n¼2
365 (159), n ¼ 4 410 (80), n ¼ 3

0 (0), n ¼ 3

0 (0), n ¼ 3

0 (0), n ¼ 3

0 (83), n ¼ 5
9.5 (142), n ¼ 5

3 (3.5), n ¼ 2
0 (0), n ¼ 1

11 (3.5), n ¼ 1
4.5 (2.1), n ¼ 2
5.4 (1.3), n ¼ 2
5 (4.5), n ¼ 2
4425 (2227),
n¼1
1300 (578),
n¼3
1325 (339),
n¼2
1667 (1155),
n¼2
0 (0), n ¼ 1
0 (0), n ¼ 1
0 (0), n ¼ 3

66–72 Hours

0 (0), n ¼ 3
900 (636), n ¼ 1

2038 (1255),
n¼4
2958 (2940),
n¼3
1 (0.7), n ¼ 1
1 (0.7), n ¼ 1
0.1 (1), n ¼ 5

6 (2.1), n ¼ 1
4.25 (3.6), n ¼ 5
2.8 (3.6), n ¼ 5
3.1 (2.3), n ¼ 3
2900 (2404),
n¼1
633 (631), n ¼ 5

54– 60 Hours

200 (150),
n¼1
179 (128),
n¼2
NA

NA
3.5 (1.0), n ¼ 2
1.5 (1.5), n ¼ 2
NA
NA

100 (115),
n¼2
NA

0 (125), n ¼ 2

NA
NA
100 (115),
n¼2
NA
NA

1000 (1075),
n¼2
578 (492),
n¼2
NA

NA
2 (1.7), n ¼ 2
1.5 (1.5), n ¼ 2
NA
NA

78– 84 Hours

Sheele et al.
Duration and severity of cholera
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(n583); left against medical advice (n511); transferred out of the cholera rehydration ward to another
part of the hospital due to ongoing other medical
concerns (n50); suffered a clinical adverse event
from study participation as determined by the treating physician (n50); a subject study’s request to be
removed from the study (n56); anuric for 24 hours
(n50); no stool for 24 hours (n50) or in the study
for a total of 14 days (n50). There were no reported
adverse events and study investigators did not contact study subjects after leaving the study.
We calculated correlations between stool number
and volume, urine number and volume and emesis
number and volume, and those correlations with a
P-value of v0.05 were the number of stools recorded
every 6 hours was correlated with the volume of
stool, the number and volume of emesis and
number of times the study subject urinated. The
volume of stool was correlated with the number
and volume of emesis and the number and volume
of urine. The number of times there was emesis was
correlated with the volume of emesis. The number
of times a person urinated was correlated with the
volume of urine. There were no other correlations
between our measured variables that were statistically significant.
The average time that subjects were in the study
for each treatment arm was 19.8 hours for BS,
26.4 hours for placebo, 34.2 for S. boulardii. and
33 hours for S. boulardii z BS. A Kruskal-Wallis
test statistic for the maximum reported hours
between the different treatment groups was 10.87
with a P-value of 0.012 indicating that patients in
the different treatment arms stayed in the hospital
for different lengths of time. Figure 1 shows the
length of time study subjects participated in the
study separated by their treatment arm.
We did repeated measures analysis with the 6, 12,
18, and an average of the values for 24 hours and
beyond for the number and volume of stool, urine
and emesis of the study subjects with the covariates
as treatment, time, and the intersection between
treatment and time. The analysis was done with the
help of Generalised Estimating Equations (GEE).
Three of the six outcomes were frequencies, so we
utilised a Poisson regression model. For the volume
measurements we used a normal (Gaussian)
regression. The P-values indicate no statistically significant effect of the treatment interventions on the
length of stay in the study (Table 3). Figures 2 and
3 show the mean number and volume of stool
respectively for each treatment arm reported every
6 hours until there were less than three study subjects
remaining in the arm for that time point.
We utilised a regression model for each of the six
response variables (number and volume of stool,

Duration and severity of cholera

number and volume of emesis, and number and
volume of urination) up until the study subject
either left against medical advice, requested removal
from the study, or was discharged. We determined
that the different treatment arms did not have any
statistically significant effects on the average length
of stay in the study. The number of stools, emesis
and urine every 6 hours was modelled as Poisson
variables and the volume measurements as normal
variables. The analysis showed insignificant Pvalues indicating that the interventions did not have
statistically different effects on he length of stay in
the study (Table 4).

Discussion
We report the first human clinical trial using BS and
S. boulardii in cholera patients. In the current study,
neither BS, S. boulardii nor BS plus S. boulardii was
shown to be effective at reducing the duration and
severity of cholera. Our initial power calculations
overestimated the level of sickness of our study subjects. It is possible that a larger sample size would
show that one of our treatment arms had beneficial
effect on the reduction and duration of symptoms.
There may have been a trend for BS to reduce the
duration and number of stools in cholera patients
compared with placebo however it did not reach statistical significance. There were no reported adverse
events from study participation, and no deaths
occurred in our study subjects while they were participating in our study.
Our data do not support the small number of
animal and in vitro studies that suggest that
S. boulardii and BS are effective at reducing the
effects of CT. In the animal studies, the benefits of
S. boulardii and BS came from pretreatment or concurrent exposure to CT. It is possible that either
S. boulardii or BS could have benefit in prophylaxis
against cholera, although that hypothesis was not
tested in this study.

Limitations
The initial physician impression on the level of dehydration at presentation to the cholera rehydration
centre was not available to study investigators. One
person on the placebo arm was recorded as having
42 stools between 6 and 12 hours of being in the
study, and while this was likely recorded in error it
was reported in our final analysis.
Patients were asked to remember the number of
stools, emesis and urine in the previous 6 hours
introducing recall bias. The time of day that the
data was recorded may have affected the number
of stools recorded (e.g. study subjects may have
produced less stools at night). On occasion a
research assistants had to estimate volumes when
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Figure 1 The number of hours each study subject was enrolled in the study separated by treatment arm. SB 5 S. boulardii,
BS 5 bismuth subsalicylate
Table 3 Analysis of variables using the generalised estimating equations (GEE).
Chi-square (P-value)
Outcome

Treatment (df¼ 3)

Time (df ¼ 1)

Treatment*time (df ¼ 3)

Stool frequency
Stool volume
Emesis frequency
Emesis volume
Urine frequency
Urine volume

1.48 (0.68)
2.73 (0.44)
Model did not converge
2.12 (0.55)
0.6 (0.90)
2.1 (0.55)

13.33 (0.0003)
9.74 (0.0018)

3.63 (0.30)
1.58 (0.66)

5.36 (0.02)
0.1 (0.75)
1.45 (0.22)

1.66 (0.65)
0.96 (0.80)
3.71 (0.29)

df ¼ degrees of freedom. (P-values)

Figure 2 The mean number of stools for each treatment arm reported every 6 hours until there were less than three study
subjects remaining in the arm for that time point. A two order polynomial trendline is recorded for the placebo arm and the
bismuth subsalicylate (BS) arm. Error bars show the 95% confidence interval with an alpha of 0.05. SB 5 S. boulardii
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Figure 3 The mean volume of stool in millilitres for each treatment arm reported every 6 hours until there were less than
three study subjects remaining in each arm for that time point. A two order polynomial trendline is recorded for the
placebo arm and the bismuth subsalicylate (BS) arm. Error bars show the 95% confidence interval with an alpha of 0.05.
SB 5 S. boulardii
Table 4 Results of a regression model for each response
variable to determine if there is an affect on length of study
participation
Outcome

Chi-Square ( p-value)
Treatment (df ¼ 3)

Stool frequency
Stool volume
Emesis frequency
Emesis volume
Urine frequency
Urine volume

0.41 (0.9382)
4.66 (0.1981)
6.37 (0.0949)
2.01 (0.5707)
1.76 (0.6238)
0.99 (0.8035)

stool was mixed with urine. Our study population
was not as sick as we had initially anticipated and
our subjects did not remain in the study for as
long as we originally expected. The study was
underpowered to determine a smaller effect of our
treatment interventions on the duration and severity of cholera

Conclusion
While BS and S. boulardii appear safe in cholera
patients, our study does not support their use as
adjunct treatments. Our study was underpowered to
identify smaller effects of these treatments on the
duration and severity of cholera.
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